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ABSTRACT
Objectives: The objective of this study was to develop a
Korean version of the original English version of BASDAI
(Bath Ankylosing Spondylitis Disease Activity Index) and to
evaluate its reliability and validity in Korean patients with
Ankylosing Spondylitis (AS).
Methods: A total of 50 outpatients diagnosed as AS by the
modiﬁed New York criteria participated. To develop a
Korean version of the BASDAI, we followed rigorous inter-
national translation steps and evaluated reliability and valid-
ity by calculating Cronbach’s alpha and correlation
coefﬁcients between BASDAI score and clinical parameters
(e.g., ESR, CRP, modiﬁed Schober test index, ﬁnger-to-
ground index, and Bath Ankylosing Spondylitis Radiologic
Index Score, and bone mineral density).
Results: Cronbach’s alpha (= 0.75) was acceptable. The
distribution of item responses evaluated by the ceiling and
ﬂoor effects showed appropriate proportions and a good
discrimination with the Korean version of the BASDAI. The
correlations among the mean BASDAI score and ﬁve scales
for the convergent validity was signiﬁcantly correlated with
each other (all P-values < 0.01). The correlations between the
BASDAI score and both erythrocyte sedimentation rate and
C-reactive protein for the criterion validity were positively
correlated (all P-values < 0.05). The results of this study
showed that the Korean translation of the BASDAI is an
efﬁcient tool in terms of its reliability and validity for the
measurement of the disease activity in patients with AS.
Conclusions: The Korean version of the BASDAI could be
used in clinical research to assess and evaluate the course of
disease activity in Korean AS patients.
Keywords: ankylosing spondylitis, BASDAI, disease activity,
Korean validation.
Introduction
Ankylosing spondylitis (AS) is a chronic, progressive,
and inﬂammatory disorder, primarily affecting the sar-
coiliac joints of the pelvis, the axial skeleton, and
thoracic cage [1]. Pain, stiffness, and bony ankylosis
cause variable degrees of restricted mobility of the
spine with consequent loss of functional capacity [2],
and impairment and disability are important compo-
nents of the patient’s perception of the disease [3].
Assessment of variations in disease activity and sever-
ity is essential to evaluate the course of disease and
treatment effects in patients with AS [4]. In assessment
of AS, many single-component measures have been
used in terms of function [2,5], metrology [6], radiol-
ogy [7], global status [8], and disease activity [9]. The
patient-assessed instruments are becoming increasingly
important in the measurement of health outcomes in
rheumatology, and provide supplementary informa-
tion to traditional biomedical assessments [10].
The Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) is identiﬁed as a patient-assessed
instrument that is reliable, valid, comprehensive, sensi-
tive to change, and reﬂects the entire spectrum of
disease, and therefore is the appropriate instrument for
deﬁning disease activity in AS [10,11]. Although the
BASDAI has been translated into several languages
[11–16], no speciﬁc questionnaire exists for measuring
such disease activity forKoreanASpatients.We focused
on the validation process to ensure that a Korean
version of BASDAI is equally clear, precise, and equiva-
lent in all ways to the original English BASDAI to have
the adequate validity and reliability [17]. The objective
of this study was to develop a Korean version of
BASDAI and to evaluate its reliability and validity for
use in clinical research and application.
Methods
Subjects
This study was conducted at a rheumatology center in
a tertiary referral university hospital in Korea. A total
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number of patients with AS who were registered to this
center were 102 (n = 102) at the initiation of the study.
We consecutively recruited outpatients diagnosed as
AS by the modiﬁed New York criteria [18,19]. Patients
were excluded from this study if they were postmeno-
pausal or pregnant women, had liver or kidney disease,
had injury on lumbar vertebrae or femur, had pre-
vious fracture history of the bones, and those with a
condition which have altered bone mineral contents
and metabolism. A total of 50 patients (mean age,
30.0  6.8) met the eligibility criteria. Information
about the study and conﬁdentiality was given to each
patient, and the informed consent was obtained. Most
were males (n = 46; 92%). The mean body mass index
(BMI) was 21.6  2.9 kg/m2. Duration of disease was
79.7  62.9 months. The mean administered steroid
unit was 4.5  12.7 (Table 1).
Translation Steps of the Korean Version of BASDAI
We followed rigorous international translation steps
based on Fayers and Marchin’s guideline [17]. We
obtained a written approval for developing a Korean
version of BASDAI from the original author. Two
trained bilingual Koreans translated the original
English BASDAI into Korean independently. Both
translators rated each item and a visual analog scale
(VAS) for its conceptual equivalence to the original
English version of BASDAI using 0 (not at all equiva-
lent) to 100 (exactly equivalent) scales. Translated
items and VAS that were rated less than 75 on the 0 to
100 scale were retranslated by the original translators
and a group of specialists, including two rheumatolo-
gists, one research nurse, and one biostatistician until
an acceptable independent rating of equivalence is
obtained. We then produced the ﬁrst draft of forward
translation. A pilot test was conducted for cognitive
testing in 15 patients with AS. In this pilot test, we
examined whether patients were confused or had dif-
ﬁculties in understanding any item, ambiguous or
annoyed in the translation. The draft of forward trans-
lation was then reﬁned and ﬁnalized after rewording
some of the items and VAS based on patients’ feed-
back. The ﬁnal forward translation was translated
back to English version (back translation) by two bilin-
gual native English speakers. Two backward translated
versions were compared against the original English
BASDAI to check and compare the conceptual consis-
tency. The ﬁnal Korean version of BASDAI was com-
pleted. We performed a ﬁeld test using this Korean
version of BASDAI and assessed its reliability and the
validity.
Assessments
Disease activity assessment. The BASDAI consists
of a 10-cm horizontal VAS and is used to answer six
questions pertaining to ﬁve major symptoms of AS:
fatigue, back pain, peripheral pain/swelling, areas of
localized tenderness, and morning stiffness. BASDAI
score is converted to 0 for “none (best)” to 10 for
“very severe (worst)” scale, with a lower score indicat-
ing less disease activity. The mean of the two scores of
morning stiffness (quantity and quality) counted as one
variable. The ﬁnal BASDAI score is deﬁned by calcu-
lating the mean of ﬁve items [9].
The modiﬁed Schober’s test and ﬁnger-to-ground
test [20] were performed by a rheumatologist. The
modiﬁed Schober’s test is the most useful index for
detecting limitation of spinal mobility for measuring
activity of AS [21]. A mean ﬂexion measurement by
modiﬁed Schober test was converted to 0 to 10. The
higher score means the more severe the patients’ limi-
tation ofmovement for their AS is [6]. Finger-to-ground
distance (trunk forward ﬂexion) is a reliable, valid, and
responsive measurement for AS patients. The smaller
distance means the greater movement [20].
Demographic and clinical assessment. Demographics
and disease-related characteristics including age, sex,
weight, height, BMI (kg/m2), and disease duration
since occurrence of back pain, vertebral stiffness,
peripheral involvement, and other manifestations were
assessed. The steroid dose administered was recorded
as a unit (the equivalent dose of prednisolone
5 mg ¥ month).
Laboratory assessment. Both Westergren erythrocyte
sedimentation rate (ESR) and serum C-reactive protein
(CRP) were assessed. The ESR was measured with the
Westergren method (mm/h) and the CRP was mea-
sured with the turbidmetric method (mg/l). Serum
calcium and phosphorus levels, liver and renal func-
tion tests (blood urea nitrogen (BUN), creatinine, total
Table 1 Demographics and clinical characteristics of subjects
(n = 50)
Parameters n (%) or mean SD
Sex, Male:Female 46 (92.0):4 (8.0)
Age, years 30.0 6.8
BMI (kg/m2) 21.6 2.9
Duration of ankylosing spondylitis (months) 79.7 62.9
Steroid (unit dose) 4.5 12.7
CRP (mg/dL) 2.4 2.5
ESR (mm/h) 35.3 31.3
Modiﬁed Schober (cm) 3.19 2.1
Finger-to-ground (cm) 20.5 14.9
BASRI-s (N = 47)
0 14 (29.8)
1 6 (12.8)
2 8 (17.0)
3 5 (10.6)
4 14 (29.8)
BMI, body mass index (calculated as weight in kg divided by height in m2); AS,
ankylosing spondylitis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
BASRI-s, Bath Ankylosing Spondylitis Radiologic Index Score; unit dose, dose equiva-
lent of prednisolone 5 mg ¥month.
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bilirubin, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT)) were also assessed.
Two levels of disease activity groups according to ESR
or CRP were deﬁned as the following: disease activity
group for ESR  15 mm/h versus normal group for
ESR < 15 mm/h, and disease activity group for CRP 
1.4 mg/dL versus normal group for CRP < 1.4 mg/dL)
[22].
Radiological and bone mineral density assessments.
Radiological assessment was performed ac-
cording to the Bath Ankylosing Spondylitis Radiologi-
cal Index Score (BASRI-s). Both anteroposterior and
lateral lumbar spine radiographs were examined. The
ﬁlms were scored by a radiologist who had over
10 years of experience and read by picture archieving
and communication system (PACS, Piviewstar, Inﬁnitt
Inc., Korea). The score ranged from 0 to 4: grade
0 = normal or no change, grade 1 = secuspicious or no
deﬁnite change, grade 2 = mild or minimum abnormal-
ity, grade 3 = moderate, and grade 4 = secevere abnor-
mality. For a lumbar spine, both anteroposterior and
lateral radiographs were examined and scored together.
If one view shows less change than the other, the overall
score will be determined to the view showing the more
signiﬁcant change [23]. Bone mineral density (BMD)
was measured at a lumbar spine and a proximal femur
(neck, greater trochanter, intertrochater area, and
Ward’s triangle) by dual energy x-ray absorptiometry
(DEXA) (QDR 4500A, Hologic, USA) to determine the
relationship between the BMD and the disease activity
parameters such as BASDAI score, modiﬁed Schober
test, ﬁnger-to-ground test and BASRI-s.
Statistical analyses. Reliability was assessed by Cron-
bach’s alpha. Convergent validity and criterion valid-
ity were examined by Pearson correlation coefﬁcients
between the BASDAI score and various clinical param-
eters (such as ESR, CRP, modiﬁed Schober’s test index,
ﬁnger-to-ground test index, BASRI-s, and BMD). The
BASDAI score, modiﬁed Schober’s test index, ﬁnger-
to-ground test index, and BASRI-s between normal
group and disease activity group classiﬁed by ESR or
CRP level were examined by the independent two-
sample t-test. Statistical signiﬁcance was P-value less
than 0.05. All statistical data analysis was carried out
using the SAS (version 9.1, Cary, NC, USA).
Results
Internal consistency reliability by Cronbach’s alpha of
the Korean version of BASDAI was 0.75. The distri-
bution of item responses of the Korean BASDAI was
good. There were no high proportions of both ceiling
and ﬂoor effects except the peripheral pain scale (ﬂoor
effect = 24%) with a range of 0 to 9.5% (Table 2). For
the convergent validity, Pearson correlation coefﬁ-
cients between the BASDAI score and fatigue, back
pain, peripheral pain, tenderness and stiffness were
moderate to high (r = 0.45, 0.75, 0.66, 0.80, 0.83;
all P-values < 0.001). For the criterion validity, the
Korean BASDAI score was positively correlated with
both CRP and ESR (P-values < 0.05). Nevertheless,
there were no signiﬁcant correlations between the
Korean BASDAI score and modiﬁed Schober test
index, ﬁnger-to-ground test index and BASRI-s
(Table 3). The ESR was positively correlated with the
scales of tenderness (r = 0.42; P < 0.05) and morning
stiffness (r = 0.33; P < 0.05). The CRP showed positive
correlations with the scales of peripheral pain, tender-
ness, and morning stiffness (r = 0.29, 0.42, 0.27, all
P-values < 0.05) (Table 4). The BASDAI score and ten-
derness between normal and disease activity group
classiﬁed by the ESR or CRP were signiﬁcantly lower
in the normal group than those in the disease activity
group (P < 0.05) (Table 5).
Discussion and Conclusion
We have cross-culturally developed a Korean version
of BASDAI, and the results of the study showed good
internal consistency reliability and both convergent
and criterion validity. Both ﬂoor and ceiling effects
were acceptable.
There were no problematic scales in the translation
steps during the development of the Korean version of
BASDAI. In cognitive testingwith 15AS patients, Cron-
bach’s alpha was 0.85, and all the ﬁve scales and the
mean BASDAI score were positively correlated with
each other. Unlike the original English BASDAI scale,
Table 2 Mean scale scores, variability (SD, ﬂoor and ceiling effects) and internal consistency reliability of the Korean BASDAI
Scales Mean SD Range Floor % Ceiling % Cronbach’s a
BASDAI 4.72 1.79 1.0–8.0 2.0 2.0 0.751
Fatigue 5.73 1.83 2.0–10.0 2.0 2.0
Back pain 5.54 2.35 0.0–10.0 6.0 2.0
Peripheral pain 2.84 2.63 0.0–9.5 24.0 2.0
Tenderness 4.38 2.89 0.0–10.0 4.0 4.0
Morning stiffness 5.13 2.78 0.0–10.0 4.0 2.0
BASDAI: BASDAI score = [Score of fatigue + back pain + peripheral pain + tenderness + (morning stiffness quantity + quality/2)]/5.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.
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the Korean translation of the BASDAI included the
phrase of “during the past week” in each of the six
questions, respectively, to make a linguistically proper
Korean sentence. In the ﬁeld study, Cronbach’s alpha of
the Korean BASDAIwas acceptable (= 0.75). Haywood
[10] and Biasi [24] reported also similar range of
Cronbach’s alphas (0.87 and 0.839, respectively). The
Korean BASDAI did not show high proportions of both
ceiling and ﬂoor effects (ranged 0–9.5%), except a high
proportion of ﬂoor effect in the peripheral pain scale
(24%). A high proportion of ﬂoor percentage effect
in the peripheral pain scale might be explained by the
study sample, which consisted mostly of men because
diagnosis of AS is frequently missed in women unless a
high degree of suspicion exists. Unlike in women, men
tend to have more involvement in spine than peripheral
joint [21,25].
The validity of this study was similar to the previous
reports [8–10], and indicated that the Korean version
of BASDAI have good discrimination. For the con-
vergent validity, all the scales of the Korean BASDAI
showed moderate to high correlations (r = 0.45–0.83).
Nevertheless, the correlations between fatigue and
other parameters showed negligible to weak correla-
tions (r = 0.15–0.33). The fatigue scale was previously
overlooked although this was an important and
common symptom in AS [26]. Fatigue can be deﬁned
either as a progressive impairment of generating capac-
ity of muscle (peripheral or muscle fatigue) or a less-
ened capacity for work and reduced efﬁciency of
accomplishment, and is usually accompanied by a
feeling of weariness, sleepiness, and irritability [27]. In
healthy subjects, this phenomenon is of natural occur-
rence, but in patients it is considered a lack of energy
Table 3 Pearson correlation coefﬁcients among scales of the Korean BASDAI for convergent validity
Pearson correlation coefﬁcients (n = 50)
BASDAI Fatigue Back pain Peripheral pain Tenderness
Fatigue 0.45* —
Back pain 0.75* 0.33† —
Peripheral pain 0.66* 0.22 0.28† —
Tenderness 0.80* 0.16 0.48* 0.39‡ –
Morning stiffness 0.83* 0.15 0.59* 0.38‡ 0.67*
*P < 0.001; †P < 0.05; ‡P < 0.01.
BASDAI: BASDAI score = (Score of fatigue + back pain + peripheral pain + tenderness + [morning stiffness quantity + quality/2])/5.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.
Table 4 Pearson correlation coefﬁcients between the Korean BASDAI score and clinical parameters for criterion validity
Pearson correlation coefﬁcients (n = 50)
BASDAI Fatigue Back pain Peripheral pain Tenderness Stiffness
ESR 0.36* -0.04 0.20 0.26 0.42* 0.33†
CRP 0.38* 0.12 0.19 0.29† 0.42* 0.27†
Modiﬁed Schober -0.01 -0.00 -0.12 -0.11 -0.13 -0.01
Finger-to-ground -0.05 -0.14 0.07 -0.16 0.02 -0.01
BASRI-S -0.06 0.11 0.10 -0.17 -0.06 -0.01
Lumbar BMD -0.08 0.01 -0.15 -0.10 -0.00 -0.04
Femur BMD 0.11 -0.06 0.11 0.17 0.02 0.13
*P < 0.01, †P < 0.05.
BASDAI: BASDAI score = (Score of fatigue + back pain + peripheral pain + tenderness + [morning stiffness quantity + quality/2])/5.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BASRI-s, Bath Ankylosing Spondylitis Radiologic Index
Score; BMD (g/cm2), bone mineral density; Femur BMD (neck, greater trochanter, intertrochanter, and Ward’s triangle).
Table 5 Criterion validity of the Korean BASDAI score by the ESR or CRP
Parameters
By ESR By CRP
No activity Disease activity No activity Disease activity
BASDAI 4.05 1.69 5.17 5.82* 4.23 1.87 5.26 1.56*
Fatigue 5.83 1.70 5.67 1.93 5.69 1.78 5.77 1.92
Back pain 4.78 2.55 6.05 2.09 5.04 2.58 6.08 1.98
Peripheral pain 2.38 2.61 3.15 2.64 2.52 2.39 3.19 2.88
Tenderness 2.98 2.30 5.32 2.90* 3.35 2.71 5.50 2.70†
Morning stiffness 4.31 2.92 5.68 2.58 4.55 2.99 5.77 2.43
*P < 0.05, †P < 0.01.
Disease activity group by ESR: ESR 15 mm/h (n = 30); no activity: ESR < 15 mm/h (n = 20).
Disease activity group by CRP: CRP 1.4 mg/dL (n = 24); no activity: CRP < 1.4 mg/dL (n = 26).
BASDAI: BASDAI score = (Score of fatigue + back pain + peripheral pain + tenderness + [morning stiffness quantity + quality/2])/5.
ESR, erythrocy sedimentation rate (mm/h); CRP, C-reactive protein (mg/dL).
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[28]. This issue of fatigue might be explained by the
limitation of small sample size, and/or the Korean AS
patients could not discriminate whether fatigue was
caused by their disease process or a simple tiredness.
Even disease status, in terms of disease activity, disease
progression, and prognosis are difﬁcult to deﬁne in
AS [29]. Both ESR and CRP are frequently used
parameters to evaluate patients with AS for acute
phase reactants [30]. Although the previous research
reported that results between the ESR and CRP and
disease activity in AS were ambiguous, or the CRP was
a better marker of disease than the ESR [22,31], there
were signiﬁcant weak correlations for the criterion
validity between the Korean BASDAI score and both
ESR and CRP (r = 0.34, r = 0.39) in this study. Fur-
thermore, to explain weak correlations we found
between the Korean BASDAI score and both ESR and
CRP, we classiﬁed two disease activity groups (normal
and active) by the proper cutoff levels of the ESR and
CRP. Both mean BASDAI score and tenderness in the
normal group were signiﬁcantly lower than those in
the disease activity group (P < 0.05). The results indi-
cated that the Korean BASDAI score might be a good
indicator to assess the acute disease activity. Neverthe-
less, because both CRP and ESR were assessed cross-
sectionally in the study, longitudinal assessment of the
ESR and CRP is required to identify disease activity
process. To reﬂect the multidimensional domains
of diseases’ impact, there is a need to include both
patient-assessed speciﬁc and generic health-related
quality of outcome measures and range of motion
(ROM) measures in the evaluation of patients with AS
[32]. Unlike Haywood’s results [20] that the modiﬁed
Schober index and ﬁngertip-to-ground distance had
adequate relationships with the BASDAI score, the
Korean BASDAI score of this study, however, did not
show signiﬁcant differences with either the modiﬁed
Schober index or ﬁnger-to-ground distance. In addi-
tion, the Korean BASDAI also showed negligible cor-
relations with BASRI-s, lumbar BMD, and femur
BMD. On the other hand, we found signiﬁcant corre-
lations between BASRI-s and modiﬁed Scober index
(r = 0.72; P < 0.0001), ﬁnger-to-ground distance
(r = 0.33; P < 0.05) and femur BMD (r = -0.35;
P < 0.05). These ﬁndings might be explained by spinal
mobility, which was better identiﬁed by radiological
ﬁndings. Averns et al. (1996) [33] reported that char-
acteristics of radiological change is essential for the
diagnosis of AS, and is considered the “gold standard”
for disease status. Mackay et al. (1998) [7,23] also
reported that BASRI-s is disease-speciﬁc, sensitive to
change, valid, simple, and rapid to perform.
The results of the study support the applications of
the Korean version of BASDAI in studies of assessing
and evaluating the Korean AS patients. The reliability
and validity of Korean translation of BASDAI was
veriﬁed.
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